Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy, or Who Have the T315I Mutation
Protocol ID
Ponatinib-1501 /AALL1922
Disease (Sub Disease)
Leukaemia (ALL)
Diagnosis Stage
Relapse/ refractory
Location
VIC, WA
Sponsor
Takeda
Links
Trial Status
Open
Sites
Royal Children's Hospital
Perth Children's Hospital
Perth Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
1 Year to 21 Years
International registry ID's
NCT04501614
| Study Title | A Pivotal Phase 1/2 Single-Arm Open-label Study to Evaluate the Safety and Efficacy of Ponatinib with Chemotherapy in Pediatric Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Who Have Relapsed or Are Resistant or Intolerant to a Prior Tyrosine Kinase Inhibitor-Containing Therapy or Who Have the T315I Mutation |
|---|---|
| Protocol ID | Ponatinib-1501 /AALL1922 |
| Disease (Sub Disease) | Leukaemia (ALL) |
| Diagnosis Stage | Relapse/ refractory |
| Location | VIC / WA |
| Sponsor | Takeda |
| Links | https://clinicaltrials.gov/ct2/show/NCT04501614 |
| Trial Status | Open |
| Trial Open Date | 21/02/2021 |
| Sites | Royal Children's Hospital / Perth Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | 1 Year to 21 Years |
| International registry ID's | NCT04501614 |